
    
      Primary Objective:

        -  To estimate the proportion of patients with donor derived engraftment at day 100 post
           transplant as defined by 80% or greater donor cells in the CD3 (T cell) fraction

      Secondary Objectives:

        -  To determine the incidence and severity of graft-versus-host disease (GVHD) by day 100

        -  To determine the incidence of peri-transplant mortality (death by day 100)

        -  To monitor donor cell chimerism at various time points following allogeneic
           transplantation with this transplant regimen as determined at day 28, 42, 100, 6 months
           and yearly for 5 years.
    
  